Heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-01. Numbers and descriptions here follow the published literature rather than marketing material.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Modeled on tuftsin |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Seven residues |
| Approximate molecular mass | Around 750 Da | Depends on counter-ion and hydration |
| Common forms | Lyophilized powder | Also described as aqueous solution |
| Primary origin of research | Russian laboratories | Mid-1990s onward |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
A small portion of approximately 3% of testosterone is reversibly converted in the liver into androstenedione by 17β-HSD. In addition to conjugation and the 17-ketosteroid pathway, testosterone can also be hydroxylated and oxidized in the liver by cytochrome P450 enzymes, including CYP3A4, CYP3A5, CYP2C9, CYP2C19, and CYP2D6. 6β-Hydroxylation and to a lesser extent 16β-hydroxylation are the major transformations. The 6β-hydroxylation of testosterone is catalyzed mainly by CYP3A4 and to a lesser extent CYP3A5 and is responsible for 75 to 80% of cytochrome P450-mediated testosterone metabolism. In addition to 6β- and 16β-hydroxytestosterone, 1β-, 2α/β-, 11β-, and 15β-hydroxytestosterone are also formed as minor metabolites. Certain cytochrome P450 enzymes such as CYP2C9 and CYP2C19 can also oxidize testosterone at the C17 position to form androstenedione. Two of the immediate metabolites of testosterone, 5α-DHT and estradiol, are biologically important and can be formed both in the liver and in extrahepatic tissues. Approximately 5 to 7% of testosterone is converted by 5α-reductase into 5α-DHT, with circulating levels of 5α-DHT about 10% of those of testosterone, and approximately 0.3% of testosterone is converted into estradiol by aromatase. 5α-Reductase is highly expressed in the male reproductive organs (including the prostate gland, seminal vesicles, and epididymides), skin, hair follicles, and brain and aromatase is highly expressed in adipose tissue, bone, and the brain.
=== Elyzol dental gel - parodontitis === Camurus has partnered with Colgate-Palmolive for the marketing of their Elyzol dental gel for the treatment of parodontitis. Elyzol 25% dental gel contains metronidazole in the form of metronidazole benzoate as the active substance.
where c is the speed of light, h is the Planck constant, α is the fine-structure constant, and R∞ is the Rydberg constant. As may be observed from the old values (2014 CODATA) in the table below, the main limiting factor in the precision of the Avogadro constant was the uncertainty in the value of the Planck constant, as all the other constants that contribute to the calculation were known more precisely.
Sources: en.wikipedia.org
Mild, Unconjugated Hyperbilirubinemia: Total serum bilirubin levels are mildly elevated, typically remaining below 6 mg/dL (102 μmol/L), with a predominance of the unconjugated (indirect) fraction. Normal Liver Function Tests: Liver enzymes, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), are within normal ranges, indicating no underlying liver disease. Absence of Hemolysis: No evidence of increased red blood cell breakdown, as indicated by normal hemoglobin levels and reticulocyte counts. Intermittent Nature of Symptoms: Episodes of jaundice that may be triggered by factors such as fasting, illness, stress, or exertion, with no other associated symptoms. The level of total bilirubin is often further increased if the blood sample is taken after fasting for two days, and a fast can, therefore, be useful diagnostically. A further conceptual step that is rarely necessary or appropriate is to give a low dose of phenobarbital: the bilirubin will decrease substantially. Exclusion of Other Liver Disorders: No clinical or laboratory evidence of other liver diseases; imaging studies and serologic tests for hepatitis are negative. Genetic Testing: Identification of mutations in the UGT1A1 gene can confirm the diagnosis of Gilbert syndrome. While not routinely required, genetic testing may be considered in cases where the diagnosis is uncertain or to provide reassurance to patients.
=== mz5 === The mz5 format addresses the performance problems present in other XML based formats (such as the above ones). It uses mzML's ontology, but saves the data using the HDF5 backend for reduced storage space requirements and improved read/write speed.
Before 1830, few Americans used ice to refrigerate foods due to a lack of ice-storehouses and iceboxes. As these two things became more widely available, individuals used axes and saws to harvest ice for their storehouses. This method proved to be difficult, dangerous, and certainly did not resemble anything that could be duplicated on a commercial scale. Despite the difficulties of harvesting ice, Frederic Tudor thought that he could capitalize on this new commodity by harvesting ice in New England and shipping it to the Caribbean islands as well as the southern states. In the beginning, Tudor lost thousands of dollars, but eventually turned a profit as he constructed icehouses in Charleston, Virginia and in the Cuban port town of Havana. These icehouses as well as better insulated ships helped reduce ice wastage from 66% to 8%. This efficiency gain influenced Tudor to expand his ice market to other towns with icehouses such as New Orleans and Savannah. This ice market further expanded as harvesting ice became faster and cheaper after one of Tudor's suppliers, Nathaniel Wyeth, invented a horse-drawn ice cutter in 1825. This invention as well as Tudor's success inspired others to get involved in the ice trade and the ice industry grew. Ice became a mass-market commodity by the early 1830s with the price of ice dropping from six cents per pound to a half cent per pound. In New York City, ice consumption increased from 12,000 tons in 1843 to 100,000 tons in 1856. Boston's consumption leapt from 6,000 tons to 85,000 tons during that same period.
Sources: en.wikipedia.org
=== Pure Leaf === Pure Leaf is an iced tea brand distributed primarily in the Americas by the PepsiCo-Lipton joint venture. Unlike Lipton Iced Tea and Brisk, which use a freeze-dried instant tea powder, Pure Leaf is brewed in liquid. The brand is sold in square bottles made of recyclable PET plastic.
=== 1982–1994 === The company established its presence in the US in 1982 via a joint venture with Squibb Corporation and Canada in 1984. In 1985, the company introduced the first insulin pen device called Novopen. In 1989, Novo Industri (Novo Terapeutisk Laboratorium) and Nordisk Gentofte (Nordisk Insulinlaboratorium) merged to become Novo Nordisk, the world's largest producer of insulin with headquarters in Bagsværd, Greater Copenhagen. In 1991, Novo Nordisk Engineering (now NNE) demerged after working as in-house consultants at Novo for years, to provide standard engineering services (end-to-end engineering) to pharma manufacturing companies. In 1994, Novo's existing information technology units was spun out as NNIT. The company was converted into a wholly owned aktieselskab in 2004. In March 2015, NNIT was floated on the Nasdaq Nordic.
Actin filament disassembly The immobilization by interpenetration of actin filaments results from two distinct ABP families. The gelsolin protein family is believed to be the most efficient in the disruption of actin filaments and is considered a "strong severing protein". These proteins respond to an increase in Ca2+ and cap the "barbed end" of the recently severed F-actin. The increased level of Ca2+ may also destabilize the actin-filament network by interfering with the binding of crosslinking proteins. The ADF/Cofilin protein family also serves to severe actin-filament networks through the weak severing of actin networks. This form of weak severing does not tightly cap the "barbed ends" but does allow for the disassociation of actin monomers and thus the disassembly of F-actin. Monomer sequestration that prevents spontaneous nucleation Exists as the turnover point in the actin remodeling cycle. The proteins thymosin and profilin prevent the spontaneous nucleation of new actin trimers. The absence or inhibition of these proteins results in the cell's ability to commence the actin remodeling cycle and produce elongated F-actin.
Sources: en.wikipedia.org
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.
It originates from research in Russia, associated with the Institute of Molecular Genetics of the Russian Academy of Sciences. The first descriptions date to the mid-1990s. Most published studies come from Russian laboratories.
No, Selank itself does not occur naturally. Its backbone is based on tuftsin, which is produced in the body, but the seven-residue version is a synthetic construct. It is supplied as a manufactured peptide.
Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.